Premium
Retreatment with telaprevir combination therapy in hepatitis C patients with well‐characterized prior treatment response
Author(s) -
Muir Andrew J.,
Poordad Fred F.,
McHutchison John G.,
Shiffman Mitchell L.,
Berg Thomas,
Ferenci Peter,
Heathcote E. Jenny,
Pawlotsky JeanMichel,
Zeuzem Stefan,
Reesink Henk W.,
Dusheiko Geoffrey,
Martin Emily C.,
George Shelley,
Kauffman Robert S.,
Adda Nathalie
Publication year - 2011
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.24549
Subject(s) - telaprevir , medicine , ribavirin , rash , adverse effect , regimen , gastroenterology , anemia , clinical trial , combination therapy , hepatitis c virus , surgery , immunology , virus
Retreatment with peginterferon alpha and ribavirin (PR) offers a limited chance of sustained virologic response (SVR) in patients who did not achieve SVR with prior PR treatment. This study evaluated the safety and efficacy of telaprevir‐based treatment in combination with PR in well‐characterized patients who did not achieve SVR in the control arms of three Phase II clinical trials. Patients eligible to enroll in this open‐label nonrandomized study either met on‐treatment criteria for nonresponse or relapsed after 48 weeks of treatment in the control arm of the three Phase II PROVE studies. The initial protocol was a 24‐week regimen: 12 weeks of telaprevir and PR followed by an additional 12 weeks of PR. During the study the protocol was amended to extend PR to 48 weeks for patients with previous null response. All other patients with undetectable hepatitis C virus (HCV) RNA at weeks 4 and 12 received 24 weeks of therapy. Those with detectable HCV RNA at weeks 4 or 12 received a total of 48 weeks of therapy. The overall SVR rate was 59% (69/117). SVR rates with T12PR were 37% (19/51) in prior null responders, 55% (16/29) in prior partial responders, 75% (6/8) in prior breakthroughs, and 97% (28/29) in prior relapsers. The overall relapse rate was 16% (13/83). Adverse events were similar to those in previous trials with telaprevir, with 9% of patients discontinuing due to an adverse event (most commonly rash and anemia). Conclusion: This study demonstrated the benefit of retreatment with a telaprevir‐based regimen for patients with well‐characterized nonresponse (null and partial) or relapse to a prior course of PR treatment. (H EPATOLOGY 2011;)